APOE ε4 carriage associates with improved myocardial performance from adolescence to older age

Topriceanu, Constantin-Cristian; Shah, Mit; Webber, Matthew; Chan, Fiona; Shiwani, Hunain; Richards, Marcus; Schott, Jonathan; Chaturvedi, Nishi; Moon, James C.; Hughes, Alun D.; Hingorani, Aroon D.; O’Regan, Declan P.; Captur, Gabriella

doi:10.1186/s12872-024-03808-z

BMC Cardiovascular Disorders

Table 3 Dose response of APOE ε4 carriage when assessing the association between APOE ε4 genotype and echocardiographic and CMR data in older age

From: APOE ε4 carriage associates with improved myocardial performance from adolescence to older age

			Model 1 (unadjusted)			Model 2 (adjusted for age, sex and SEP)		Model 3 (Model 2 + BMI)		Model 4 (Model 2 + CVD)		Model 5 (Model 2 + diabetes)		Model 6 (Model 2 + high cholesterol)		Model 7 (Model 2 + HT)
Outcome:	Cohort	Analysis	n	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value	Exp β (95% CI)	p-value
MCF	UK biobank	APOE ε4-linear	32,644	1.01 (1.00, 1.02)	0.082	1.01 (1.00, 1.02)	0.152	1.01 (1.00, 1.02)	0.239	1.01 (1.00, 1.02)	0.036	1.01 (1.00, 1.02)	0.123	1.01 (1.00, 1.02)	0.006	1.01 (1.00, 1.02)	0.109
	SABRE + NSHD meta-analysis	APOE ε4-linear	2074	1.02 (0.96, 1.08)	0.544	1.02 (0.96, 1.08)	0.516	1.03 (0.97, 1.09)	0.906	1.01 (0.95, 1.07)	0.729	1.00 (0.95, 1.07)	0.870	1.01 (0.94, 1.08)	0.780	1.01 (0.96, 1.07)	0.670
	ALSPAC	APOE ε4-linear	1325	1.00 (0.97, 1.03)	0.984	1.02 (0.96, 1.08)	0.604	1.01 (0.95, 1.07)	0.74	1.00 (0.94, 1.06)	0984	1.00 (0.95, 1.06)	0.310	0.99 (0.93, 1.05)	0.685	1.01 (0.94, 1.08)	0.874
	UK biobank	APOE ε4 -quadratic	32,644	1.00 (0.99, 1.01)	0.770	1.00 (1.00, 1.01)	0.424	1.00 (0.99, 1.01)	0.972	1.00 (1.00, 1.01)	0.687	1.00 (1.00, 1.01)	0.711	1.00 (1.00, 1.01)	0.723	1.00 (0.99, 1.01)	0.803
	SABRE + NSHD meta-analysis	APOE ε4 -quadratic	2074	0.98 (0.93, 1.03)	0.475	0.98 (0.93, 1.03)	0.451	0.99 (0.94, 1.04)	0.675	0.98 (0.94, 1.02)	0.327	0.98 (0.94, 1.02)	0.251	0.97 (0.92, 1.01)	0.174	0.98 (0.94, 1.02)	0.312
	ALSPAC	APOE ε4 -quadratic	1325	0.99 (0.98, 1.00)	0.286	1.00 (0.96, 1.04)	0.865	0.98 (0.95, 1.02)	0.281	098 (0.95, 1.02)	0.286	0.98 (0.95, 1.02)	0.326	0.97 (0.94, 1.01)	0.149	0.99 (0.95, 1.03)	0.537
Longitudinal PDSR	UK biobank	APOE ε4-linear	32,505	1.01 (0.98, 1.04)	0.557	1.00 (0.97, 1.03)	0.855	1.01 (0.97, 1.04)	0.756	1.01 (0.98, 1.04)	0.476	1.01 (0.98, 1.04)	0.678	1.02 (0.99, 1.05)	0.199	1.01 (0.97, 1.04)	0.630
Longitudinal PDSR	UK biobank	APOE ε4 -quadratic	32,505	0.99 (0.97, 1.01)	0.499	1.00 (0.98, 1.02)	0.640	0.99 (0.97, 1.01)	0.388	0.99 (0.97, 1.02)	0.524	0.99 (0.97, 1.02)	0.524	0.99 (0.97, 1.02)	0.526	0.99 (0.97, 1.01)	0.477
Radial PDSR	UK biobank	APOE ε4-linear	32,505	0.98 (0.88, 1.09)	0.725	1.02 (0.92, 1.13)	0.786	0.99 (0.89, 1.10)	0.282	0.97 (0.87, 1.08)	0.614	0.99 (0.89, 1.10)	0.858	0.95 (0.85, 1.06)	0.321	0.99 (0.88, 1.10)	0.789
Radial PDSR	UK biobank	APOE ε4 -quadratic	32,505	1.03 (0.96, 1.11)	0.379	1.02 (0.96, 1.10)	0.503	1.03 (0.96, 1.11)	0.416	1.03 (0.96, 1.11)	0.405	1.03 (0.96, 1.11)	0.400	1.03 (0.96, 1.11)	0.399	1.04 (0.96, 1.11)	0.365

The APOE ε4 genotypes were coded as an ordered category based on the number of ε4 possessed. Thus, level 0 encompassed ε2ε2, ε2ε3, ε2ε3, level 1 ε2ε4 and ε3 ε4 and level 2 ε4ε4. Given the existence of two levels, generalized linear models and orthogonal polynomial contrasts with 2 equally spaced levels (i.e., linear and quadratic) were employed to look for a dose response by ε4 variants. Significant p-values are highlighted in bold. Abbreviations as in Table 2

Back to article page

ISSN: 1471-2261

Contact us

Submission enquiries: bmccardiovasculardisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com